Hydrocortisone Activase (Hydrocortisone)

Hydrocortisone Activase is prescribed for conditions that require systemic glucocorticoid therapy.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute exacerbations of chronic inflammatory diseases such as rheumatoid arthritis.
• Treatment of severe allergic reactions when oral corticosteroids are indicated.
• Adjunctive therapy for certain autoimmune disorders, for example systemic lupus erythematosus.
• Short‑term control of inflammation in dermatologic or gastrointestinal conditions when oral administration is preferred.

• Hydrocortisone Activase acts as an agonist at intracellular glucocorticoid receptors. Upon binding, the receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, while enhancing the expression of anti‑inflammatory proteins such as annexin‑1. The overall effect is suppression of the immune response and reduction of inflammation.

Oral hydrocortisone may cause a range of adverse reactions, varying in frequency and severity.

Common

• Mild gastrointestinal upset such as nausea or dyspepsia.
• Transient increase in blood glucose levels, especially in diabetic patients.
• Fluid retention leading to mild peripheral edema.
• Mood changes including irritability or insomnia.

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus.
• Suppression of the hypothalamic‑pituitary‑adrenal axis causing adrenal crisis on abrupt discontinuation.
• Opportunistic infections due to immunosuppression.

Before initiating Hydrocortisone Activase, clinicians should evaluate several safety considerations.

• Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Screen for uncontrolled diabetes or hypertension, conditions that may be exacerbated.
• Evaluate history of peptic ulcer disease; concurrent NSAIDs increase gastrointestinal risk.
• Consider bone health, especially in long‑term therapy, due to risk of osteoporosis.
• Use the lowest effective dose and taper gradually to avoid adrenal insufficiency.
• Counsel pregnant or breastfeeding patients, as safety data are limited.

Hydrocortisone Activase can interact with other medicines, altering efficacy or safety.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure.
• Combining with other systemic corticosteroids, which can increase risk of systemic side effects.
• Use with strong immunosuppressants (e.g., cyclosporine) without monitoring, due to additive infection risk.

Use with caution

• Concomitant antidiabetic agents; hydrocortisone may raise glucose and require dose adjustment.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase gastrointestinal bleeding risk.
• Anticoagulants such as warfarin; glucocorticoids can affect clotting factor synthesis.
• Vaccines, especially live attenuated, may have reduced efficacy or cause infection.